Inhaled nitroglycerin

Phase 3Small molecule

BBeni-Suef University

Inhaled nitroglycerin is one of 13 small molecule programs targeting COPD. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

COPDRecruiting

COPDPhase 3

Recruiting

Competition

Competitive Landscape

17 competitors in COPD

#DrugCompanyPhaseTrials

Spiriva

Boehringer Ingelheim

Approved

13 2

Daliresp

AstraZeneca

Approved

2 3

Striverdi Respimat

Boehringer Ingelheim

Approved

5 4

Zithromax

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

2 5

Marinol

Jazz Pharmaceuticals

Phase 3

1 6

Inhaled nitroglycerin

BBeni-Suef University

Phase 3

1 7

Medrol

Pfizer

Preclinical

1 8

Dexpramipexole Dihydrochloride

AAreteia Therapeutics

Phase 2

1 9

DUPIXENT

Regeneron

Preclinical

—10

Xopenex Hfa

HHikma Pharmaceuticals LLC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

COPD1 trial

"The Effect of Inhaled Nitroglycerin for COPD Patients

Recruiting·—·Phase 2/3·NCT06785337·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Inhaled nitroglycerin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Inhaled nitroglycerin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Inhaled nitroglycerin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Beni-Suef University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: BBeni-Suef University

Inhaled nitroglycerin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

COPD1 trial

References

Drug Info

Quick Facts

Related News